dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Transmembrane guanylyl cyclases (type: catalytic_receptor)
Target: Guanylyl cyclase-B

Ligand: cenderitide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart.
Published in: PLoS ONE

Ligand: compound C10 [PMID: 24297249] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Identification of small molecule NPR-B antagonists by high throughput screening--potential use in heart failure.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: C-type natriuretic peptide (Peptide)
Interaction type: Agonist
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.
Published in: Endocrinology

Ligand: peptide P19 [PMID: 15652659] (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.809999942779541 pKd
Reference (Journal): Development of a selective peptide antagonist for the human natriuretic peptide receptor-B.
Published in: Peptides

Ligand: [Ser11](N-CNP,C-ANP)pBNP2-15 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Development of a selective peptide antagonist for the human natriuretic peptide receptor-B.
Published in: Peptides

Ligand: [125I]CNP (human) (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: vosoritide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA & FDA (2021)
Primary target: no
Median affinity:  -
Reference (Journal): Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Published in: Am J Hum Genet
Target family: Transmembrane guanylyl cyclases (type: catalytic_receptor)
Target: Guanylyl cyclase-D

Ligand: uroguanylin (Peptide)
Interaction type: Agonist
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Transmembrane guanylyl cyclases (type: catalytic_receptor)
Target: Guanylyl cyclase-E

Ligand: guanylyl cyclase-activating protein 1 (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: guanylyl cyclase-activating protein 2 (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Transmembrane guanylyl cyclases (type: catalytic_receptor)
Target: Guanylyl cyclase-F

Ligand: guanylyl cyclase-activating protein 1 (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: guanylyl cyclase-activating protein 2 (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Transporters (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum hexose transporter

Ligand: HTI-1 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pEC50
Reference (Journal): Structural Basis for Blocking Sugar Uptake into the Malaria Parasite Plasmodium falciparum.
Published in: Cell

Ligand: HTI-1 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.420000076293945 pEC50
Reference (Journal): Structural Basis for Blocking Sugar Uptake into the Malaria Parasite Plasmodium falciparum.
Published in: Cell
Target family: Transporters (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum non-SERCA-type Ca2+ -transporting P-ATPase

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.149999618530273 pIC50
Reference (Journal): Spiroindolones, a potent compound class for the treatment of malaria.
Published in: Science
Target family: Transporters (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum hexose transporter

Ligand: TCMDC-125163 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pEC50
Reference (Journal): Identification of Selective Inhibitors of the Plasmodium falciparum Hexose Transporter PfHT by Screening Focused Libraries of Anti-Malarial Compounds.
Published in: PLoS ONE

Ligand: TCMDC-125163 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.010000228881836 pEC50
Reference (Journal): Identification of Selective Inhibitors of the Plasmodium falciparum Hexose Transporter PfHT by Screening Focused Libraries of Anti-Malarial Compounds.
Published in: PLoS ONE
Target family: Transporters (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum Niemann-Pick type C1-related protein

Ligand: MMV009108 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.340000152587891 pEC50
Reference (Journal): <i>Plasmodium</i> Niemann-Pick type C1-related protein is a druggable target required for parasite membrane homeostasis.
Published in: Elife
Target family: Transporters (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum non-SERCA-type Ca2+ -transporting P-ATPase

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector.
Published in: Antimicrob Agents Chemother

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector.
Published in: Antimicrob Agents Chemother

Ligand: cipargamin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector.
Published in: Antimicrob Agents Chemother

Ligand: PA21A092 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.409999847412109 pEC50
Reference (Journal): Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.
Published in: Nat Commun
Target family: Transporters (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum V-type proton ATPase subunit D

Ligand: sutidiazine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.820000171661377 pIC50
Reference (Journal): Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.
Published in: Nat Commun

Ligand: sutidiazine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.
Published in: Nat Commun
Target family: Transthyretin (type: other_protein)
Target: transthyretin

Ligand: tafamidis (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA and UK (2011), FDA (2019)
Primary target: no
Median affinity: 8.699999809265137 pKd
Reference (Journal): Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Published in: Proc Natl Acad Sci USA
Target family: Tubulins (type: other_protein)
Target: tubulin beta class I

Ligand: paclitaxel (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1992), EMA (2008)
Primary target: yes
Median affinity: 8.050000190734863 pEC50
Reference (Journal): Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines.
Published in: Bioorg Med Chem Lett

Ligand: vincristine (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1963)
Primary target: yes
Median affinity:  -

Ligand: vinblastine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1965)
Primary target: yes
Median affinity: 9 pIC50

Ligand: ixabepilone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2007)
Primary target: yes
Median affinity:  -

Ligand: eribulin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2010), EMA (2011)
Primary target: yes
Median affinity: 8.229999542236328 pIC50
Reference (Journal): Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model.
Published in: Bioorg Med Chem Lett

Ligand: docetaxel (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996), EMA (1995)
Primary target: yes
Median affinity:  -

Ligand: colchicine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2009)
Primary target: yes
Median affinity: 7.960000038146973 pIC50
Reference (Journal): Synthesis and biological evaluation of B-ring modified colchicine and isocolchicine analogs.
Published in: Bioorg Med Chem Lett

Ligand: cabazitaxel (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2010), EMA (2011)
Primary target: yes
Median affinity:  -
Target family: Tubulins (type: other_protein)
Target: tubulin beta 3 class III

Ligand: combretastatin A4 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.239999771118164 pIC50
Reference (Journal): Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents.
Published in: J Med Chem
Target family: Tumour-associated antigens (type: other_protein)
Target: tumor associated calcium signal transducer 2

Ligand: hIMB1636-MMAE (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.149999618530273 pKd
Reference (Journal): hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.
Published in: J Med Chem

Ligand: sacituzumab govitecan (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2020), EMA (2021)
Primary target: yes
Median affinity:  -
Reference (Patent): RS7 antibodies.
Target family: Tumour-associated antigens (type: other_protein)
Target: folate receptor alpha

Ligand: mirvetuximab soravtansine (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2022)
Primary target: no
Median affinity: 10.100000381469727 pKd
Reference (Journal): IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Published in: Mol Cancer Ther
Target family: Tumour-associated antigens (type: other_protein)
Target: glypican 3

Ligand: codrituzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
Published in: Anticancer Drugs

Ligand: codrituzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Patent): Anti-glypican 3 antibody having modified sugar chain.
Target family: Tumour-associated antigens (type: other_protein)
Target: trophoblast glycoprotein

Ligand: anatumomab mafenatox (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.920000076293945 pKd
Reference (Journal): Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
Published in: Br J Cancer

Ligand: naptumomab estafenatox (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9 pKd
Reference (Journal): Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
Published in: J Immunother
Target family: Tumour-associated antigens (type: other_protein)
Target: tumor associated calcium signal transducer 2

Ligand: datopotamab deruxtecan (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer.
Published in: Heliyon
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: death receptor 4

Ligand: TRAIL (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: herpes virus entry mediator

Ligand: LIGHT (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: B and T lymphocyte attenuator (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: glucocorticoid-induced TNF receptor

Ligand: TL6 (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: Fas

Ligand: Fas ligand (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: ectodysplasin A2 isoform receptor

Ligand: ectodysplasin A2 (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors.
Published in: Science
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: ectodysplasin 1, anhidrotic receptor

Ligand: ectodysplasin A1 (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors.
Published in: Science
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: death receptor 5

Ligand: TRAIL (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.230000019073486 pKd
Reference (Patent): An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Ligand: tigatuzumab (Antibody)
Interaction type: Antibody
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pKd
Reference (Patent): An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Ligand: aponermin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Aponermin: First Approval.
Published in: Drugs
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: death receptor 4

Ligand: SC-67655 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pIC50
Reference (Journal): Design of MHC class II (DR4) ligands using conformationally restricted imino acids at p3 and p5.
Published in: Bioorg Med Chem Lett

Ligand: aponermin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Aponermin: First Approval.
Published in: Drugs
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: death receptor 3

Ligand: TL1A (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: CD40

Ligand: CFZ533 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.15999984741211 pKd
Reference (Patent): Silent fc variants of anti-cd40 antibodies.

Ligand: CD40 ligand (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: CD30

Ligand: CD30 ligand (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: herpes virus entry mediator

Ligand: lymphotoxin-α (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: CD30

Ligand: brentuximab vedotin (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2011), EMA (2012)
Primary target: yes
Median affinity:  -

Ligand: AFM13 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.029999732971191 pKd
Reference (Journal): A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
Published in: MAbs
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: CD27

Ligand: CD70 (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: B cell maturation antigen

Ligand: linvoseltamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.639999866485596 pEC50
Reference (Journal): A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
Published in: Blood Adv

Ligand: belantamab mafodotin (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA & EMA (2020)
Primary target: no
Median affinity: 9.819999694824219 pKd
Reference (Patent): B cell maturation antigen (BCMA) binding proteins

Ligand: BAFF (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: APRIL (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: BAFF receptor

Ligand: ianalumab (Antibody)
Interaction type: Antibody
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.720000267028809 pIC50
Reference (Patent): Compositions and methods of use for therapeutic antibodies

Ligand: BAFF (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: 4-1BB

Ligand: utomilumab (Antibody)
Interaction type: Antibody
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.0600004196167 pKd
Reference (Journal): Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.
Published in: Cancer Immunol Immunother

Ligand: urelumab (Antibody)
Interaction type: Antibody
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 7.78000020980835 pKd
Reference (Patent): Fully human antibodies against human 4-1bb (cd137)
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: lymphotoxin &beta; receptor

Ligand: lymphotoxin β2α1 heterotrimer (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: LIGHT (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: 4-1BB

Ligand: BT7480 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.430000305175781 pKd
Reference (Journal): Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology.
Published in: J Med Chem
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: TWEAK receptor

Ligand: TWEAK (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: tumor necrosis factor receptor 2

Ligand: tumour necrosis factor membrane form (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: 4-1BB

Ligand: 4-1BB ligand (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: tumor necrosis factor receptor 2

Ligand: lymphotoxin-α (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: tumor necrosis factor receptor 1

Ligand: tumour necrosis factor shed form (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: tumour necrosis factor membrane form (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: lymphotoxin-α (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: toxicity and JNK inducer

Ligand: lymphotoxin-α (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: TACI

Ligand: BAFF (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: APRIL (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: receptor activator of NF-kappa B

Ligand: RANK ligand (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -